Sun Pharmaceutical Industries Ltd. plans to acquire a
branded oncology product, Odomzo, from Novartis. The agreement has been
signed between subsidiaries of both the companies and will close following
anti-trust clearance and further closing conditions. The agreement has
been signed for an upfront payment of $175 million and additional
milestone payments.
Odomzo (Sonidegib) was approved by the U.S. FDA in
July 2015. Odomzo is a hedgehog pathway inhibitor indicated for the
treatment of adult patients with locally advanced basal cell carcinoma (laBCC)
that has recurred following surgery or radiation therapy, or those who are
not candidates for surgery or radiation therapy. About 70 percent of the
prescribers are dermatologists and rests are oncologists for this class of
drug.
New data supporting the use of Odomzo were presented
at ASCO in June 2016. Data from the BOLT trial showed continued antitumor
activity for more than 26 months in patients treated with Odomzo® with no new
safety concerns. At the 30-month follow-up, patients with locally advanced
BCC had an overall response rate (ORR) as per central review of 56% with
Odomzo® 200 mg. The most frequent grade 3 and 4 adverse reactions
occurring in more than 2% of patients were fatigue, decreased weight and
muscle spasms.
According to Mr Jesper Jensen, Head – Biologics and
Dermatology, Sun Pharma,"We look forward to collaborating with the medical
community to bring this novel therapy to the market to patients suffering from
locally advanced basal cell carcinoma. Odomzo complements and enhances our
existing Dermatology franchise. This acquisition has the potential to leverage
and expand the relationships that our Levulan sales team have with the
Dermatologists that treat common pre-cancerous skin conditions.”
0 comentários:
Postar um comentário